Structured Immunity is a protein engineering company making T cell based therapies safer by enhancing the target specificity of T cell receptors Structured Immunity is a protein engineering company specializing in the optimization and validation of T cell receptor (TCR) proteins to improve the safety of T cell based therapies.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/structured-immunity” connections=”true” suffix=””]
Structured Immunity proprietary protein engineering platform enables immuno-oncology development and integrates structural biology, immunology, and protein biophysics for predictively validating and optimizing lead TCR candidates for immunotherapy.
In Aug 2018, Structured Immunity signed research collaboration with Medigene AG, to provide structural immunology expertise in support of Medigenes TCR discovery activities. Under the terms, Medigene will supply Structured Immunity with a lead TCR candidate for a high-profile solid tumor target. Structured Immunity will evaluate the TCRs specificity and recognition properties using their established structural immunology technologies.
In May 2017, Structured Immunity received a Grant worth $15k from an undisclosed investor.